A study to look at how safe different doses of atezolizumab were for patients – and how this medicine was processed through the body

A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors

Cancer
Solid Tumors
Tumor

Results
Download
Print

Study results

LPS GO27831 Final Results October 2019 English (PDF, 0.2 MB)

LPS GO27831 Final Results October 2019 Spanish (PDF, 0.1 MB)

LPS GO27831 Final Results October 2019 French (PDF, 0.2 MB)

What is Clinical Research?

In clinical research, volunteers, researchers, and medical professionals work together toward a shared goal: better treatment outcomes for patients. Clinical trials are vital to their process. They are carefully designed and follow approved protocols.

A study to look at how safe different doses of atezolizumab were for patients – and how this medicine was processed through the body

Study results

LPS GO27831 Final Results October 2019 English (PDF, 0.2 MB)

LPS GO27831 Final Results October 2019 Spanish (PDF, 0.1 MB)

LPS GO27831 Final Results October 2019 French (PDF, 0.2 MB)

What is Clinical Research?

For the latest version of this information please go to www.forpatients.roche.com

Directly contact Roche for questions

Contact the hospital directly

Thank you

Something went wrong

Request a call back

Find participating medical centers and current study status in each of them

A study to look at how safe different doses of atezolizumab were for patients – and how this medicine was processed through the body

For the latest version of this information please go to www.forpatients.roche.com